DCM
SYRE icon

DAFNA Capital Management’s Spyre Therapeutics SYRE Stock Holding History

DAFNA Capital Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-13,984
Closed -$1.89M – 79
2017
Q4 		$1.89M Hold
13,984
– – 1.02% 32
2017
Q3 		$1.72M Hold
13,984
– – 1.07% 28
2017
Q2 		$1.35M Sell
13,984
-32
-0.2% -$4.42K 0.96% 34
2017
Q1 		$2.61M Hold
14,016
– – 2.21% 13
2016
Q4 		$1.52M Hold
14,016
– – 1.34% 31
2016
Q3 		$2.25M Hold
14,016
– – 1.56% 22
2016
Q2 		$1.7M Buy
+14,016
New +$2.69M 1.35% 21

Other funds holding SYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $863M AUM 30.35% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

DAFNA Capital Management's SYRE Position: Q1 2018 in Review

DAFNA Capital Management sold out of Spyre Therapeutics (SYRE) in Q1 2018, closing a stake of 13,984 shares — an estimated $1.89M sold.

DAFNA Capital Management first reported a position in SYRE in Q2 2016 and held it in 7 quarters. The position peaked at $2.61M in Q1 2017. 38 funds tracked by Wall St. Rank hold SYRE as of Q1 2018.

  • DAFNA Capital Management reported no remaining Spyre Therapeutics position as of Q1 2018 after selling out during the quarter.
  • DAFNA Capital Management sold 13,984 Spyre Therapeutics shares in Q1 2018, an estimated $1.89M.
  • DAFNA Capital Management first reported a position in Spyre Therapeutics in Q2 2016 and held it in 7 quarters.
  • DAFNA Capital Management's Spyre Therapeutics position peaked at $2.61M in Q1 2017.
  • 38 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2018.

Based on DAFNA Capital Management's 13F filing for Q1 2018, filed 15 May 2018.